21 results on '"Lu, Lihui"'
Search Results
2. LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1
- Author
-
Lu, Lihui, Wang, Jianwei, Fang, Fang, Guo, Ailian, Jiang, Shuting, Tao, Yanfang, Zhang, Yongping, Li, Yan, Zhang, Kunlong, Zhang, Zimu, Zhuo, Ran, Chu, Xinran, Li, Xiaolu, Tian, Yuanyuan, Ma, Li, Sang, Xu, Chen, Yanling, Yu, Juanjuan, Yang, Yang, Cao, Haibo, Gao, Jizhao, Lu, Jun, Hu, Shaoyan, Pan, Jian, and He, Hailong
- Published
- 2023
- Full Text
- View/download PDF
3. Colocalized, bidirectional optogenetic modulations in freely behaving mice with a wireless dual-color optoelectronic probe
- Author
-
Li, Lizhu, Lu, Lihui, Ren, Yuqi, Tang, Guo, Zhao, Yu, Cai, Xue, Shi, Zhao, Ding, He, Liu, Changbo, Cheng, Dali, Xie, Yang, Wang, Huachun, Fu, Xin, Yin, Lan, Luo, Minmin, and Sheng, Xing
- Published
- 2022
- Full Text
- View/download PDF
4. Luteolin-7-O-β-d-Glucuronide Attenuated Cerebral Ischemia/Reperfusion Injury: Involvement of the Blood–Brain Barrier.
- Author
-
Fan, Xing, Song, Jintao, Zhang, Shuting, Lu, Lihui, Lin, Fang, Chen, Yu, Li, Shichang, Jin, Xinxin, and Wang, Fang
- Subjects
CEREBRAL ischemia ,REPERFUSION injury ,BLOOD-brain barrier ,CORONARY heart disease treatment ,CEREBRAL infarction ,ELLAGIC acid ,HYDROCEPHALUS - Abstract
Ischemic stroke is a common cerebrovascular disease with high mortality, high morbidity, and high disability. Cerebral ischemia/reperfusion injury seriously affects the quality of life of patients. Luteolin-7-O-β-d-glucuronide (LGU) is a major active flavonoid compound extracted from Ixeris sonchifolia (Bge.) Hance, a Chinese medicinal herb mainly used for the treatment of coronary heart disease, angina pectoris, cerebral infarction, etc. In the present study, the protective effect of LGU on cerebral ischemia/reperfusion injury was investigated in an oxygen–glucose deprivation/reoxygenation (OGD/R) neuronal model and a transient middle cerebral artery occlusion (tMCAO) rat model. In in vitro experiments, LGU was found to improve the OGD/R-induced decrease in neuronal viability effectively by the MTT assay. In in vivo experiments, neurological deficit scores, infarction volume rates, and brain water content rates were improved after a single intravenous administration of LGU. These findings suggest that LGU has significant protective effects on cerebral ischemia/reperfusion injury in vitro and in vivo. To further explore the potential mechanism of LGU on cerebral ischemia/reperfusion injury, we performed a series of tests. The results showed that a single administration of LGU decreased the content of EB and S100B and ameliorated the abnormal expression of tight junction proteins ZO-1 and occludin and metalloproteinase MMP-9 in the ischemic cerebral cortex of the tMCAO 24-h injury model. In addition, LGU also improved the tight junction structure between endothelial cells and the degree of basement membrane degradation and reduced the content of TNF-α and IL-1β in the brain tissue. Thereby, LGU attenuated cerebral ischemia/reperfusion injury by improving the permeability of the blood–brain barrier. The present study provides new insights into the therapeutic potential of LGU in cerebral ischemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. An optical brain-to-brain interface supports rapid information transmission for precise locomotion control
- Author
-
Lu, Lihui, Wang, Ruiyu, and Luo, Minmin
- Published
- 2020
- Full Text
- View/download PDF
6. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
- Author
-
Ma, Li, Wang, Jianwei, Yang, Yang, Lu, Jun, Ling, Jing, Chu, Xinran, Zhang, Zimu, Tao, Yanfang, Li, Xiaolu, Tian, Yuanyuan, Li, Zhiheng, Zhang, Yongping, Sang, Xu, Lu, Lihui, Wan, Xiaomei, Zhang, Kunlong, Chen, Yanling, Yu, Juanjuan, Zhuo, Ran, and Wu, Shuiyan
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,GENE expression ,HEMATOLOGIC malignancies ,CELL cycle - Abstract
B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent malignant tumor affecting children. While the majority of B-ALL patients (90%) experience successful recovery, early relapse cases of B-ALL continue to exhibit high mortality rates. MZ1, a novel inhibitor of Bromodomains and extra-terminal (BET) proteins, has demonstrated potent antitumor activity against hematological malignancies. The objective of this study was to examine the role and therapeutic potential of MZ1 in the treatment of B-ALL. In order to ascertain the fundamental mechanism of MZ1, a sequence of in vitro assays was conducted on B-ALL cell lines, encompassing Cell Counting Kit 8 (CCK8) assay, Propidium iodide (PI) staining, and Annexin V/PI staining. Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to examine protein and mRNA expression levels. Transcriptomic RNA sequencing (RNA-seq) was utilized to screen the target genes of MZ1, and lentiviral transfection was employed to establish stably-expressing/knockdown cell lines. MZ1 has been observed to induce the degradation of Bromodomain Containing 4 (BRD4), Bromodomain Containing 3 (BRD3), and Bromodomain Containing 2 (BRD2) in B-ALL cell strains, leading to inhibited cell growth and induction of cell apoptosis and cycle arrest in vitro. These findings suggest that MZ1 exhibits cytotoxic effects on two distinct molecular subtypes of B-ALL, namely 697 (TCF3/PBX1) and RS4;11 (MLL-AF4) B-ALL cell lines. Additionally, RNA-sequencing analysis revealed that MZ1 significantly downregulated the expression of Cyclin D3 (CCND3) gene in B-ALL cell lines, which in turn promoted cell apoptosis, blocked cell cycle, and caused cell proliferation inhibition. Our results suggest that MZ1 has potential anti-B-ALL effects and might be a novel therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Microscale optoelectronic infrared-to-visible upconversion devices and their use as injectable light sources
- Author
-
Ding, He, Lu, Lihui, Shi, Zhao, Wang, Dan, Li, Lizhu, Li, Xichen, Ren, Yuqi, Liu, Changbo, Cheng, Dali, Kim, Hoyeon, Giebink, Noel C., Wang, Xiaohui, Yin, Lan, Zhao, Lingyun, Luo, Minmin, and Sheng, Xing
- Published
- 2018
8. Control of locomotor speed, arousal, and hippocampal theta rhythms by the nucleus incertus
- Author
-
Lu, Lihui, Ren, Yuqi, Yu, Tao, Liu, Zhixiang, Wang, Sice, Tan, Lubin, Zeng, Jiawei, Feng, Qiru, Lin, Rui, Liu, Yang, Guo, Qingchun, and Luo, Minmin
- Published
- 2020
- Full Text
- View/download PDF
9. Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1.
- Author
-
Zhang, Kunlong, Lu, Jun, Fang, Fang, Zhang, Yongping, Yu, Juanjuan, Tao, Yanfang, liu, Wenyuan, Lu, Lihui, Zhang, Zimu, Chu, Xinran, Wang, Jianwei, Li, Xiaolu, Tian, Yuanyuan, Li, Zhiheng, Li, Qian, Sang, Xu, Ma, Li, Wang, Ningling, Pan, Jian, and Hu, Shaoyan
- Subjects
REGULATOR genes ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,T cells ,GENE enhancers - Abstract
Background. Arising from T progenitor cells, T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignant tumor, accounting for 15% of childhood ALL and 25% of adult ALL. Composing of putative enhancers in close genomic proximity, super enhancer (SE) is critical for cell identity and the pathogenesis of multiple cancers. Belonging to the cytosolute linker protein group, FYB1 is essential for TCR signaling and extensively studied in terms of tumor pathogenesis and metastasis. Dissecting the role of FYN binding protein 1 (FYB1) in T-ALL holds the potential to improve the treatment outcome and prognosis of T-ALL. Methods. In this study, SEs were explored using public H3K27ac ChIP-seq data derived from T-ALL cell lines, AML cell lines and hematopoietic stem and progenitor cells (HSPCs). Downstream target of FYB1 gene was identified by RNA-seq. Effects of shRNA-mediated downregulation of FYB1 and immunoglobulin lambda-like polypeptide 1 (IGLL1) on self-renewal of T-ALL cells were evaluated in vitro and/or in vivo. Results. As an SE-driven gene, overexpression of FYB1 was observed in T-ALL, according to the Cancer Cell Line Encyclopedia database. In vitro, knocking down FYB1 led to comprised growth and enhanced apoptosis of T-ALL cells. In vivo, downregulation of FYB1 significantly decreased the disease burden by suppressing tumor growth and improved survival rate. Knocking down FYB1 resulted in significantly decreased expression of IGLL1 that was also an SE-driven gene in T-ALL. As a downstream target of FYB1, IGLL1 exerted similar role as FYB1 in inhibiting growth of T-ALL cells. Conclusion. Our results suggested that FYB1 gene played important role in regulating self-renewal of T-ALL cells by activating IGLL1, representing a promising therapeutic target for T-ALL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
- Author
-
Sang, Xu, Zhang, Yongping, Fang, Fang, Gao, Li, Tao, Yanfang, Li, Xiaolu, Zhang, Zimu, Wang, Jianwei, Tian, Yuanyuan, Li, Zhiheng, Yao, Di, Wu, Yumeng, Chu, Xinran, Zhang, Kunlong, Ma, Li, Lu, Lihui, Chen, Yanling, Yu, Juanjuan, Zhuo, Ran, and Wu, Shuiyan
- Subjects
ACUTE myeloid leukemia ,POLY(ADP-ribose) polymerase ,GENE targeting ,ANTINEOPLASTIC agents ,INHIBITION of cellular proliferation ,SUPER enhancers ,PROTEINS ,NUCLEAR proteins ,ANIMAL experimentation ,CELL cycle proteins ,CELL physiology ,APOPTOSIS ,TRANSCRIPTION factors ,CELL lines ,MICE - Abstract
Background: AML (acute myeloid leukemia) is a common hematological malignancy in children with poor treatment effects and poor prognosis. Recent studies have shown that as a novel BRD4 (bromodomain containing 4) PROTACs (proteolysis targeting chimeras) degrader, GNE-987 can slow down the growth of various tumors and increase apoptosis, with promising clinical prospects. However, the function and molecular mechanism of GNE-987 in AML remain unclear. This study is aimed at investigating the therapeutic effect of GNE-987 on AML and its underlying mechanism.Methods: The association between BRD4 and AML was assessed by studying public databases. After GNE-987 was added to AML cells, cell proliferation slowed down, the cycle was disturbed, and apoptosis increased. Western blotting was used to detect BRD2 (bromodomain containing 2), BRD3 (bromodomain containing 3), BRD4, and PARP (poly ADP-ribose polymerase) proteins. The effect of GNE-987 on AML cells was analyzed in vivo. RNA-seq (RNA sequencing) and ChIP-seq (chromatin immunoprecipitation sequencing) validated the function and molecular pathways of GNE-987 in processing AML.Results: BRD4 expression was significantly elevated in pediatric AML samples compared with healthy donors. GNE-987 inhibited AML cell proliferation by inhibiting the cell cycle and inducing apoptosis. BRD2, BRD3, and BRD4 were consistent with decreased VHL (Von Hippel Lindau) expression in AML cells. In an AML xenograft model, GNE-987 significantly reduced the hepatosplenic infiltration of leukemia cells and increased the mouse survival time. Based on analysis of RNA-seq and ChIP-seq analyses, GNE-987 could target multiple SE- (super-enhancer-) related genes, including LYL1 (lymphoblastic leukemia 1), to inhibit AML.Conclusions: GNE-987 had strong antitumor activity in AML. GNE-987 could effectively inhibit the expression of SE-related oncogenes including LYL1 in AML. Our results suggested that GNE-987 had broad prospects in the treatment of AML. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
- Author
-
Ma, Li, Wang, Jianwei, Zhang, Yongping, Fang, Fang, Ling, Jing, Chu, Xinran, Zhang, Zimu, Tao, Yanfang, Li, Xiaolu, Tian, Yuanyuan, Li, Zhiheng, Sang, Xu, Zhang, Kunlong, Lu, Lihui, Wan, Xiaomei, Chen, Yanling, Yu, Juanjuan, Zhuo, Ran, Wu, Shuiyan, and Lu, Jun
- Subjects
ACUTE myeloid leukemia ,ANTINEOPLASTIC agents ,BLOOD diseases ,PROTEOLYSIS ,SUBSTANCE abuse relapse - Abstract
Acute myeloid leukemia (AML) is a highly cancerous and aggressive hematologic disease with elevated levels of drug resistance and relapse resulting in high mortality. Recently, bromodomains and extra-terminal (BET) protein inhibitors have been extensively researched in hematological tumors as potential anticancer agents. MZ1 is a novel BET inhibitor that mediates selective proteins degradation and suppression of tumor growth through proteolysis-targeting chimeras (PROTAC) technology. Accordingly, this study aimed to investigate the role and therapeutic potential of MZ1 in AML. In this study, we first identified that AML patients with high BRD4 expression had poor overall survival than those with low expression group. MZ1 inhibited AML cell growth and induced apoptosis and cycle arrest in vitro. MZ1 induced degradation of BRD4, BRD3 and BRD2 in AML cell strains. Additionally, MZ1 also initiated the cleavage of poly-ADP-ribose polymerase (PARP), which showed cytotoxic effects on NB4 (PML-RARa), K562 (BCR-ABL), Kasumi-1 (AML1-ETO), and MV4-11 (MLL-AF4) cell lines representing different molecular subtypes of AML. In AML mouse leukemia model, MZ1 significantly decreased leukemia cell growth and increased the mouse survival time. According to the RNA-sequencing analysis, MZ1 led to c-Myc and ANP32B genes significant downregulation in AML cell lines. Knockdown of ANP32B promoted AML cell apoptosis and inhibited cell growth. Overall, our data indicated that MZ1 had broad anti-cancer effects on AML cell lines with different molecular lesions, which might be exploited as a novel therapeutic strategy for AML patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Degradation of PVC waste into a flexible polymer by chemical modification using DINP moieties.
- Author
-
Lu, Lihui, Kumagai, Shogo, Kameda, Tomohito, Luo, Ligang, and Yoshioka, Toshiaki
- Published
- 2019
- Full Text
- View/download PDF
13. Tracking the timing and nature of protolith, metamorphism, and partial melting of tourmaline‐bearing migmatites by zircon U–Pb and Hf isotopic compositions in the Yuka terrane, North Qaidam UHP metamorphic belt.
- Author
-
Gao, Shunbao, Chen, Xin, Xu, Rongke, Cai, Pengjie, Lu, Lihui, Hou, Weidong, Guo, Xianzheng, and Liu, Y.
- Subjects
TRACE elements ,RARE earth metals ,ZIRCON ,BORON isotopes ,NATURE ,MELT crystallization ,FLUID inclusions - Abstract
An integrated study using cathodoluminescence (CL) images, U–Pb geochronology, and Hf isotopic characterization of zircons was performed on migmatites from the Yuka terrane to provide insights into the timing and nature of the protoliths, metamorphism, and partial melting of these rocks. Zircon grains separated from the migmatites have three distinct domains. Residual zircon cores in samples YKT01 and YKT02 exhibit oscillatory zoning, high Th/U ratios (0.10–0.79), steep heavy rare earth element (HREE) patterns, and mean ages of 936 ± 5 Ma and 927 ± 11 Ma, respectively, indicating that they are igneous in origin and record Neoproterozoic magmatism during the Grenvillian Orogeny. CL‐grey cores record an ultrahigh‐pressure (UHP) peak metamorphism age of 435 ± 5 Ma and have low Th/U and 176Lu/177Hf ratios, weak negative Eu anomalies, and relatively flat HREE patterns. The CL‐bright rims have steep HREE patterns with lower middle rare earth element (MREE) concentrations but higher HREE concentrations compared with the metamorphic cores and a weighted average age of 422 ± 4 Ma, which records the timing of melt crystallization. The migmatites incorporate garnet relicts coexisting with fluid inclusions and hydrous minerals like peritectic phengite and peritectic large anhedral poikilitic tourmaline in the leucosomes. Peak temperatures are less than 750°C, suggesting that the anatectic melts may be derived from melting of felsic gneiss in the presence of water. The timing of melt crystallization is ca. 13 Ma later than UHP metamorphism, indicating that the partial melting took place during the exhumation stage. The metamorphic zircon cores have higher 176Hf/177Hf(t) ratios than the residual magmatic cores, which provides powerful evidence for the generation of the metamorphic zircons through the incorporation of internal high Hf minerals other than zircon in a closed system. Anatectic rims with lower 176Hf/177Hf(t) ratios but higher 176Lu/177Hf ratios than metamorphic cores suggest that the main formation mechanism is dissolution‐reprecipitation of pre‐existing zircons. In conclusion, the elevated 176Hf/177Hf(t), TDM2 age and decreasing 176Lu/177Hf(t) ratios in the metamorphic and anatectic domains imply that the new zircons in some migmatites and granites may not reflect the Hf isotope compositions of their source rocks, accounting for the variable Hf isotope compositions in S‐type granites. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Inhibition of Receptor Interacting Protein Kinases Attenuates Cardiomyocyte Hypertrophy Induced by Palmitic Acid.
- Author
-
Zhao, Mingyue, Lu, Lihui, Lei, Song, Chai, Hua, Wu, Siyuan, Tang, Xiaoju, Bao, Qinxue, Chen, Li, Wu, Wenchao, and Liu, Xiaojing
- Published
- 2016
- Full Text
- View/download PDF
15. Decoupling control scheme for pulsed GMAW process of aluminum
- Author
-
Lu, Lihui, Fan, Ding, Huang, Jiankang, and Shi, Yu
- Subjects
- *
GAS metal arc welding , *ALUMINUM , *ELECTRON donor-acceptor complexes , *ELECTRIC arc , *CONTROL theory (Engineering) - Abstract
Abstract: A double-variable decoupling control scheme was proposed for GMAW-P process of aluminum helping to efficiently develop welding procedure. Weld pool width and arc length were both measured through vision sensing in welding process. Weld bead shape was improved by changing the current waveforms to adjust the heat input while the arc length was controlled to stabilize the welding process. An experimental system was developed to sense, observe and control the welding process real-timely. Experiments were conducted to verify the effectiveness of the scheme. The results show that good weld bead shape and stable welding process can be obtained through the double-variable decoupling control scheme without complex metal transfer control and considerable trial and error to identify suitable combinations of welding parameters in GMAW-P. This control scheme provides an alternative to obtain proper weld quality for GMAW-P. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. NPM-ALK Mutants in Kinase Domain Exhibit Altered Kinase Activity and Various Sensitivity to ALK Inhibitors.
- Author
-
Lu, Lihui, Ghose, Arup, Quail, Matt, Ruggeri, Bruce, and Cheng, Mangeng
- Published
- 2008
- Full Text
- View/download PDF
17. Identification and Characterization of an ALK Inhibitor That Attenuates the Proliferation and Survival of Anaplastic Large Cell Lymphoma-Derived Cell Lines and ALK Dependent Cell Lines.
- Author
-
Cheng, Mangeng, Wan, Weihua, Albom, Mark, Weinberg, Linda, Angeles, Thelma, Quail, Matthew, Lu, Lihui, Underiner, Ted, Hudkins, Robert, Ator, Mark, and Ruggeri, Bruce
- Published
- 2004
- Full Text
- View/download PDF
18. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
- Author
-
Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, and Hu S
- Subjects
- Humans, Cell Cycle Proteins metabolism, Cell Line, Tumor, Intercellular Signaling Peptides and Proteins, Proteolysis, Proto-Oncogene Proteins c-myc, Transcription Factors metabolism, Leukemia, Myeloid, Acute pathology, Nuclear Proteins metabolism
- Abstract
Acute myeloid leukemia (AML) represents an aggressive hematopoietic malignancy with a prognosis inferior to that of other leukemias. Recent targeted therapies offer new opportunities to achieve better treatment outcomes. However, due to the complex heterogeneity of AML, its prognosis remains dismal. In this study, we first identified the correlation between high expression of BRD4 and overall survival of patients with AML. Targeted degradation of BRD2, BRD3, and BRD4 proteins by dBET1, a proteolysis-targeting chimera (PROTAC) against the bromodomain and extra-terminal domain (BET) family members, showed cytotoxic effects on Kasumi (AML1-ETO), NB4 (PML-RARa), THP-1 (MLL-AF9), and MV4-11 (MLL-AF4) AML cell lines representing different molecular subtypes of AML. Furthermore, we determined that dBET1 treatment arrested cell cycling and enhanced apoptosis and c-MYC was identified as the downstream target. Collectively, our results indicated that dBET1 had broad anti-cancer effects on AML cell lines with different molecular lesions and provided more benefits to patients with AML., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Zhang, Gao, Wang, Chu, Zhang, Zhang, Fang, Tao, Li, Tian, Li, Sang, Ma, Lu, Chen, Yu, Zhuo, Wu, Pan and Hu.)
- Published
- 2022
- Full Text
- View/download PDF
19. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
- Author
-
Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, and Ruggeri BA
- Subjects
- Administration, Oral, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Benzocycloheptenes chemistry, Biological Availability, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Female, Humans, Immunoblotting, Interleukin Receptor Common gamma Subunit deficiency, Interleukin Receptor Common gamma Subunit genetics, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Lung Neoplasms pathology, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse metabolism, Lymphoma, Large B-Cell, Diffuse pathology, Mice, Mice, Inbred NOD, Mice, Knockout, Mice, Nude, Mice, SCID, Molecular Structure, Neoplasms metabolism, Neoplasms pathology, Neuroblastoma drug therapy, Neuroblastoma metabolism, Neuroblastoma pathology, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors pharmacokinetics, Pyrimidines chemistry, Receptor Protein-Tyrosine Kinases metabolism, Antineoplastic Agents pharmacology, Benzocycloheptenes pharmacology, Neoplasms drug therapy, Protein Kinase Inhibitors pharmacology, Pyrimidines pharmacology, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Xenograft Model Antitumor Assays
- Abstract
Anaplastic lymphoma kinase (ALK) is constitutively activated in a number of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent molecular target for cancer therapy. Here we report the identification and preclinical characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor. CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation. It induced concentration-dependent growth inhibition/cytotoxicity of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 hours following single oral dosing at 30 mg/kg. Dose-dependent antitumor activity was observed in ALK-positive ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions observed following treatment at doses of 30 mg/kg twice daily or higher. Treatment of mice bearing Sup-M2 tumor xenografts for 4 weeks and primary human ALCL tumor grafts for 2 weeks at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment. Conversely, CEP-28122 displayed marginal antitumor activity against ALK-negative human tumor xenografts under the same dosing regimens. Administration of CEP-28122 was well tolerated in mice and rats. In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.
- Published
- 2012
- Full Text
- View/download PDF
20. Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.
- Author
-
Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV, Underiner TL, Curry MA, Quail MR, Lu L, Wan W, Angeles TS, Albom MS, Aimone LD, Ator MA, Ruggeri BA, and Dorsey BD
- Abstract
A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivatives within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK). These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines. The lead inhibitor 15, which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-positive ALCL cells. Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-positive ALCL tumor xenografts in Scid mice.
- Published
- 2010
- Full Text
- View/download PDF
21. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
- Author
-
Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR, Reddy DR, Holskin BP, Angeles TS, Underiner TL, Meyer SL, Hudkins RL, Dorsey BD, Ator MA, Ruggeri BA, and Cheng M
- Subjects
- Anaplastic Lymphoma Kinase, Apoptosis, Carbazoles pharmacology, Caspases metabolism, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Gene Expression Regulation, Neoplastic, Humans, Indazoles pharmacology, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse pathology, Phenylurea Compounds pharmacology, Protein-Tyrosine Kinases antagonists & inhibitors, Protein-Tyrosine Kinases metabolism, Receptor Protein-Tyrosine Kinases, Cell Division physiology, Cell Survival physiology, Lymphoma, Large B-Cell, Diffuse enzymology, Protein-Tyrosine Kinases genetics
- Abstract
The roles of aberrant expression of constitutively active ALK chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well defined; nevertheless, the notion that ALK is a molecular target for the therapeutic modulation of ALK+ ALCL has not been validated thus far. Select fused pyrrolocarbazole (FP)-derived small molecules with ALK inhibitory activity were used as pharmacologic tools to evaluate whether functional ALK is essential for the proliferation and survival of ALK+ ALCL cells in culture. These compounds inhibited interleukin 3 (IL-3)-independent proliferation of BaF3/NPM-ALK cells in an ALK inhibition-dependent manner and significantly blocked colony formation in agar of mouse embryonic fibroblast (MEF) cells harboring NPM-ALK. Inhibition of NPM-ALK phosphorylation in the ALK+ ALCL-derived cell lines resulted in significant inhibition of cell proliferation and induction of apoptotic-cell death, while having marginal effects on the proliferation and survival of K562, an ALK- leukemia cell line. ALK inhibition resulted in cell-cycle G1 arrest and inactivation of ERK1/2, STAT3, and AKT signaling pathways. Potent and selective ALK inhibitors may have therapeutic application for ALK+ ALCL and possibly other solid and hematologic tumors in which ALK activation is implicated in their pathogenesis.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.